An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

​ Conditions: Cardiovascular Disease and Lipoprotein(a)

Interventions: Drug: Pelacarsen (TQJ230)

Sponsors: Novartis Pharmaceuticals

Recruiting Conditions: Cardiovascular Disease and Lipoprotein(a)
Interventions: Drug: Pelacarsen (TQJ230)
Sponsors: Novartis Pharmaceuticals
Recruiting